Immunogenicity assessment – Choice of an appropriate platform is crucial

The most common technology to evaluate ADA response is the enzyme-linked immunosorbent assay (ELISA) by the bridging assay format. The new immunoassay platforms at IBR Inc., AlphaLISA^®, MSD^® ECL and Gyrolab™, expand the choice and offer considerable advantages in terms of sensitivity, accuracy, robustness, reduced assay time and sample consumption, better drug- and target tolerance, dynamic range and detection of low affinity ADAs.

Prior to assay validation and subsequent analysis of clinical samples selection of the most appropriate technology is crucial and needs careful evaluation.

Immunoassay platforms

The ELISA is the most commonly used assay to evaluate ADA response. Bridging format assays show high target tolerance even in the absence of target depletion.
The Gyrolab™ ADA solution provides an automated nanoliter-scale method with or without acid pre-treatment and uses dedicated Gyrolab™ ADA software designed for 21 CFR part 11 compliance. The technology is especially suitable for studies with small sample volumes.
The Meso Scale Discovery® (MSD) platform allows multiplex assay formats and offers rapid development of MSD bridging immunogenicity assays with a homogeneous solution phase incubation step where only one wash step is required.
The AlphaLISA® platform is a proximity-based homogeneous assay that relies on energy transfer between donor and acceptor beads with a high signal amplification. Sensitivity of ADA detection can be achieved on the ng/ml scale. Drug tolerance is high at µg/ml concentrations of free drug.

Carefully selecting the appropriate platform can improve success. IBR Inc. invites you to discuss your requirements with its scientific experts, ensuring the proper choice of technology platform (ELISA, AlphaLISA®, Gyrolab™ or MSD®) as well as sample pre-treatment strategies, tailored to your specific needs.

Flyers

Immunogenicity assay setup and optimization

IBR Inc. develops immunogenicity assays in direct or bridging format. During the assay development, sample pre-treatment strategies to reach an appropriate target and drug tolerance are carefully evaluated. Acid dissociation, target depletion and ECL-based PandA method are some of the strategies that might be employed. Neutralizing capacity can be evaluated by non cell-based or cell-based assays, depending on the particular mechanism of action of the specific drug.

Assay validation

Analysis of clinical trial samples must be performed using appropriately validated methods with adequate acceptance criteria. IBR Inc. assay validation is conducted following regulatory requirements and validation guidelines EMEA/CHMP/EWP/192217/2009, ICH Q2 (R1) and USP Chapter 1033.

Clinical sample measurement

Analysis of clinical trial samples for the assessment of the immunogenic potential, is done by a tiered approach, following the regulatory guidelines EMEA/CHMP/BMWP/14327/2006.

Screening for binding ability of ADAs
Confirmatory assay on selected positive samples
Neutralizing capacity (non cell-based and cell-based assays)

Submit a Question or Request

Simply fill out the form below and a member of our team will follow up with you shortly.

Company*

Website*

First Name*

Last Name*

Email*

Phone Number*

Email (repeat)*

is human*

Your Request

Data Protection*

I accord my agreement for the usage and processing of my personal data for the purpose of processing my inquiry (see Privacy Policy). I am aware that I have the right to object the processing of my data at any time and with effect for the future.